Details of the Drug

General Information of Drug (ID: DMSQ8MD)

Drug Name
Anagrelide
Synonyms
Anagrelida; Anagrelidum; BL 416201; Agrylin (TN); Anagrelida [INN-Spanish]; Anagrelide [BAN:INN]; Anagrelide [INN:BAN]; Anagrelidum [INN-Latin]; Xagrid (TN); Anagrelide (INN/BAN); 6,7-Dichlor-1,5-dihydroimidazo(2,1-b)chinazolin-2(3H)-on; 6,7-Dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one; 6,7-dichloro-1,5-dihydroimidazo[2,1-]quinazolin-2(3H)-one; 6,7-dichloro-5,10-dihydro-3H-imidazo[2,1-b]quinazolin-2-one
Indication
Disease Entry ICD 11 Status REF
Thrombocythemia 3B63 Approved [1], [2]
Essential thrombocythemia 3B63.1Z Phase 2 [3]
Therapeutic Class
Antithrombotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 256.079
Topological Polar Surface Area (xlogp) 1.6
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [4]
Bioavailability
The bioavailability of drug is 70% [4]
Elimination
Less than 1% of drug is recovered in the urine as unchanged parent drug, while approximately 3% and 16-20% of the drug is recovered as 3-hydroxy anagrelide and RL603, respectively [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 hours [4]
Metabolism
The drug is metabolized via the liver [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.55784 micromolar/kg/day [5]
Chemical Identifiers
Formula
C10H7Cl2N3O
IUPAC Name
6,7-dichloro-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
Canonical SMILES
C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3
InChI
InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)
InChIKey
OTBXOEAOVRKTNQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
135409400
ChEBI ID
CHEBI:142290
CAS Number
68475-42-3
DrugBank ID
DB00261
TTD ID
D0D1HW
INTEDE ID
DR0112
ACDINA ID
D00038

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3A (PDE3A) TT06AWU PDE3A_HUMAN Inhibitor [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 1A2 (CYP1A2)
Main DME 		DEJGDUW CP1A2_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 03 Disease of the blood or blood-forming organs
Disease Class ICD-11: 3B64 Thrombocytopenia
The Studied Tissue Whole blood
The Studied Disease Thrombocythemia [ICD-11:3B64]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 3A (PDE3A) DTT PDE3A 3.33E-01 1.35E-02 0.14
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 6.75E-01 4.94E-02 4.06E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Anagrelide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Anagrelide and Ivosidenib. Acute myeloid leukaemia [2A60] [27]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Anagrelide and Midostaurin. Acute myeloid leukaemia [2A60] [28]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Anagrelide and Idarubicin. Acute myeloid leukaemia [2A60] [28]
Daunorubicin DMQUSBT Major Increased risk of prolong QT interval by the combination of Anagrelide and Daunorubicin. Acute myeloid leukaemia [2A60] [28]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Anagrelide and Arn-509. Acute myeloid leukaemia [2A60] [28]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Anagrelide and Gilteritinib. Acute myeloid leukaemia [2A60] [28]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Anagrelide and Oliceridine. Acute pain [MG31] [28]
Terfenadine DM4KLPT Major Increased risk of prolong QT interval by the combination of Anagrelide and Terfenadine. Allergic/hypersensitivity disorder [4A80-4A8Z] [28]
Tacrine DM51FY6 Moderate Decreased metabolism of Anagrelide caused by Tacrine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [29]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Galantamine. Alzheimer disease [8A20] [28]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Rivastigmine. Alzheimer disease [8A20] [28]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Donepezil. Alzheimer disease [8A20] [28]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Anagrelide and Metronidazole. Amoebiasis [1A36] [29]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Ivabradine. Angina pectoris [BA40] [30]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Anagrelide and Bepridil. Angina pectoris [BA40] [28]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Anagrelide and Dronedarone. Angina pectoris [BA40] [28]
Nifedipine DMSVOZT Moderate Decreased metabolism of Anagrelide caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [29]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Anagrelide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Alprazolam DMC7XDN Moderate Decreased metabolism of Anagrelide caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [29]
Hydroxyzine DMF8Y74 Major Increased risk of prolong QT interval by the combination of Anagrelide and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [28]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Anagrelide caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [29]
Promazine DMZAL7W Major Increased risk of prolong QT interval by the combination of Anagrelide and Promazine. Appearance/behaviour symptom [MB23] [28]
Voriconazole DMAOL2S Major Increased risk of prolong QT interval by the combination of Anagrelide and Voriconazole. Aspergillosis [1F20] [28]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Anagrelide and Posaconazole. Aspergillosis [1F20] [28]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Levalbuterol. Asthma [CA23] [31]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Anagrelide and Terbutaline. Asthma [CA23] [32]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Pirbuterol. Asthma [CA23] [32]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Salbutamol. Asthma [CA23] [33]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Anagrelide caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [30]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Formoterol. Asthma [CA23] [32]
Zileuton DMVRIC2 Moderate Decreased metabolism of Anagrelide caused by Zileuton mediated inhibition of CYP450 enzyme. Asthma [CA23] [34]
Atomoxetine DM5L6HI Major Increased risk of prolong QT interval by the combination of Anagrelide and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [28]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Anagrelide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [28]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Anagrelide and Desipramine. Attention deficit hyperactivity disorder [6A05] [28]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Anagrelide caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [34]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Anagrelide and Ofloxacin. Bacterial infection [1A00-1C4Z] [28]
Ciprofloxacin XR DM2NLS9 Major Increased risk of prolong QT interval by the combination of Anagrelide and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [28]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Anagrelide and Clarithromycin. Bacterial infection [1A00-1C4Z] [28]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Anagrelide and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [28]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Anagrelide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [35]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Anagrelide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [28]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Anagrelide and Norfloxacin. Bacterial infection [1A00-1C4Z] [28]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Anagrelide and Levofloxacin. Bacterial infection [1A00-1C4Z] [28]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Anagrelide and Lomefloxacin. Bacterial infection [1A00-1C4Z] [28]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Anagrelide and Telithromycin. Bacterial infection [1A00-1C4Z] [28]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Anagrelide and Retigabine. Behcet disease [4A62] [28]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Loperamide. Bowel habit change [ME05] [36]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Anagrelide and Eribulin. Breast cancer [2C60-2C6Y] [28]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Anagrelide and Lapatinib. Breast cancer [2C60-2C6Y] [28]
Tamoxifen DMLB0EZ Major Increased risk of prolong QT interval by the combination of Anagrelide and Tamoxifen. Breast cancer [2C60-2C6Y] [28]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Anagrelide and Toremifene. Breast cancer [2C60-2C6Y] [28]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Anagrelide and Bosutinib. Breast cancer [2C60-2C6Y] [28]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Anagrelide and Grepafloxacin. Bronchitis [CA20] [35]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Anagrelide and Sotalol. Cardiac arrhythmia [BC9Z] [28]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Anagrelide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [28]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [32]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [31]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Salmeterol. Chronic obstructive pulmonary disease [CA22] [32]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [32]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [32]
Pentosan polysulfate DM2HRKE Moderate Increased risk of bleeding by the combination of Anagrelide and Pentosan polysulfate. Chronic pain [MG30] [37]
Phenylbutazone DMAYL0T Moderate Increased risk of bleeding by the combination of Anagrelide and Phenylbutazone. Chronic pain [MG30] [38]
Ketoprofen DMRKXPT Moderate Increased risk of bleeding by the combination of Anagrelide and Ketoprofen. Chronic pain [MG30] [38]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Anagrelide and Levomilnacipran. Chronic pain [MG30] [39]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Anagrelide and Regorafenib. Colorectal cancer [2B91] [30]
Oxaliplatin DMQNWRD Major Increased risk of prolong QT interval by the combination of Anagrelide and Oxaliplatin. Colorectal cancer [2B91] [28]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Anagrelide and Intedanib. Colorectal cancer [2B91] [40]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Anagrelide and Isoproterenol. Conduction disorder [BC63] [32]
Levobupivacaine DM783CH Moderate Decreased metabolism of Anagrelide caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [30]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Anagrelide and Halothane. Corneal disease [9A76-9A78] [28]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Propofol. Corneal disease [9A76-9A78] [41]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Anagrelide and Sevoflurane. Corneal disease [9A76-9A78] [28]
Lidocaine DML4ZOT Moderate Decreased metabolism of Anagrelide caused by Lidocaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [29]
Ropivacaine DMSPJG2 Moderate Decreased metabolism of Anagrelide caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [29]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Anagrelide and Probucol. Coronary atherosclerosis [BA80] [28]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Anagrelide and Ardeparin. Coronary thrombosis [BA43] [42]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Anagrelide and Methadone. Cough [MD12] [28]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Anagrelide and Clofazimine. Crohn disease [DD70] [28]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Anagrelide and Mifepristone. Cushing syndrome [5A70] [28]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Anagrelide and Pasireotide. Cushing syndrome [5A70] [28]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Anagrelide and Osilodrostat. Cushing syndrome [5A70] [28]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Anagrelide and Danaparoid. Deep vein thrombosis [BD71] [42]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Anagrelide and Rivaroxaban. Deep vein thrombosis [BD71] [43]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Anagrelide and Sertraline. Depression [6A70-6A7Z] [28]
Trimipramine DM1SC8M Major Increased risk of prolong QT interval by the combination of Anagrelide and Trimipramine. Depression [6A70-6A7Z] [28]
Fluoxetine DM3PD2C Major Increased risk of prolong QT interval by the combination of Anagrelide and Fluoxetine. Depression [6A70-6A7Z] [28]
Nortriptyline DM4KDYJ Major Increased risk of prolong QT interval by the combination of Anagrelide and Nortriptyline. Depression [6A70-6A7Z] [28]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Anagrelide and Vilazodone. Depression [6A70-6A7Z] [39]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Anagrelide and Paroxetine. Depression [6A70-6A7Z] [39]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Anagrelide and Vortioxetine. Depression [6A70-6A7Z] [39]
Duloxetine DM9BI7M Moderate Increased risk of bleeding by the combination of Anagrelide and Duloxetine. Depression [6A70-6A7Z] [39]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Anagrelide and Milnacipran. Depression [6A70-6A7Z] [39]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Anagrelide and Escitalopram. Depression [6A70-6A7Z] [28]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Anagrelide and Desvenlafaxine. Depression [6A70-6A7Z] [39]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Anagrelide and Clomipramine. Depression [6A70-6A7Z] [28]
Trazodone DMK1GBJ Major Increased risk of prolong QT interval by the combination of Anagrelide and Trazodone. Depression [6A70-6A7Z] [28]
Amitriptyline DMK7F9S Major Increased risk of prolong QT interval by the combination of Anagrelide and Amitriptyline. Depression [6A70-6A7Z] [28]
Mirtazapine DML53ZJ Major Increased risk of prolong QT interval by the combination of Anagrelide and Mirtazapine. Depression [6A70-6A7Z] [28]
Protriptyline DMNHTZI Major Increased risk of prolong QT interval by the combination of Anagrelide and Protriptyline. Depression [6A70-6A7Z] [28]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Anagrelide and Doxepin. Depression [6A70-6A7Z] [28]
Maprotiline DMPWB7T Major Increased risk of prolong QT interval by the combination of Anagrelide and Maprotiline. Depression [6A70-6A7Z] [28]
Venlafaxine DMR6QH0 Major Increased risk of prolong QT interval by the combination of Anagrelide and Venlafaxine. Depression [6A70-6A7Z] [28]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Anagrelide and Heme. Discovery agent [N.A.] [44]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Anagrelide and Apigenin. Discovery agent [N.A.] [45]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Anagrelide caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [29]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Anagrelide and PMID28870136-Compound-49. Discovery agent [N.A.] [28]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Anagrelide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [28]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Anagrelide and Deutetrabenazine. Dystonic disorder [8A02] [28]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Anagrelide and Ingrezza. Dystonic disorder [8A02] [28]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Anagrelide and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [39]
Stiripentol DMMSDOY Moderate Decreased metabolism of Anagrelide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Phenobarbital DMXZOCG Moderate Increased metabolism of Anagrelide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Carbamazepine DMZOLBI Moderate Increased metabolism of Anagrelide caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Suprofen DMKXJZ7 Moderate Increased risk of bleeding by the combination of Anagrelide and Suprofen. Eye anterior segment structural developmental anomaly [LA11] [38]
Mefenamic acid DMK7HFI Moderate Increased risk of bleeding by the combination of Anagrelide and Mefenamic acid. Female pelvic pain [GA34] [38]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Anagrelide and Solifenacin. Functional bladder disorder [GC50] [28]
Pentamidine DMHZJCG Major Increased risk of prolong QT interval by the combination of Anagrelide and Pentamidine. Fungal infection [1F29-1F2F] [28]
Ketoconazole DMPZI3Q Major Increased risk of prolong QT interval by the combination of Anagrelide and Ketoconazole. Fungal infection [1F29-1F2F] [28]
Omeprazole DM471KJ Moderate Increased metabolism of Anagrelide caused by Omeprazole mediated induction of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [29]
Cimetidine DMH61ZB Moderate Decreased metabolism of Anagrelide caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [34]
Cisapride DMY7PED Major Increased risk of prolong QT interval by the combination of Anagrelide and Cisapride. Gastro-oesophageal reflux disease [DA22] [28]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Anagrelide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [28]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Anagrelide and Avapritinib. Gastrointestinal stromal tumour [2B5B] [30]
Carvedilol DMHTEAO Moderate Decreased metabolism of Anagrelide caused by Carvedilol mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [29]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Anagrelide caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Rifampin DMA8J1G Moderate Increased metabolism of Anagrelide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [29]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Anagrelide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [28]
Tipranavir DM8HJX6 Major Increased risk of bleeding by the combination of Anagrelide and Tipranavir. Human immunodeficiency virus disease [1C60-1C62] [46]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Anagrelide and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [47]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Anagrelide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [48]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Anagrelide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Anagrelide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [28]
Verapamil DMA7PEW Moderate Decreased metabolism of Anagrelide caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [34]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Anagrelide caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [30]
Givosiran DM5PFIJ Moderate Decreased metabolism of Anagrelide caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [34]
Meclofenamic acid DM05FXR Moderate Increased risk of bleeding by the combination of Anagrelide and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [38]
Ramelteon DM7IW9J Moderate Decreased metabolism of Anagrelide caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [49]
Melatonin DMKWFBT Moderate Decreased metabolism of Anagrelide caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [29]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Anagrelide caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [50]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Anagrelide caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [29]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Polyethylene glycol. Irritable bowel syndrome [DD91] [30]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Phenolphthalein. Irritable bowel syndrome [DD91] [28]
Alosetron DML2A03 Moderate Decreased metabolism of Anagrelide caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [51]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Anagrelide and Crizotinib. Lung cancer [2C25] [28]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Anagrelide and Ceritinib. Lung cancer [2C25] [28]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Anagrelide and Osimertinib. Lung cancer [2C25] [28]
Capmatinib DMYCXKL Moderate Decreased metabolism of Anagrelide caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [34]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Anagrelide and Selpercatinib. Lung cancer [2C25] [28]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Anagrelide and Lumefantrine. Malaria [1F40-1F45] [29]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Anagrelide and Halofantrine. Malaria [1F40-1F45] [52]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Anagrelide and Chloroquine. Malaria [1F40-1F45] [53]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Anagrelide and Hydroxychloroquine. Malaria [1F40-1F45] [53]
Quinine DMSWYF5 Major Increased risk of prolong QT interval by the combination of Anagrelide and Quinine. Malaria [1F40-1F45] [28]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Anagrelide and Primaquine. Malaria [1F40-1F45] [28]
Mefloquine DMWT905 Major Increased risk of prolong QT interval by the combination of Anagrelide and Mefloquine. Malaria [1F40-1F45] [28]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Anagrelide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [28]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [54]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Anagrelide and Acalabrutinib. Mature B-cell lymphoma [2A85] [55]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Anagrelide and Ibrutinib. Mature B-cell lymphoma [2A85] [56]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Anagrelide and Ponatinib. Mature B-cell lymphoma [2A85] [57]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Anagrelide and LGX818. Melanoma [2C30] [28]
Propranolol DM79NTF Moderate Decreased metabolism of Anagrelide caused by Propranolol mediated inhibition of CYP450 enzyme. Migraine [8A80] [29]
Riluzole DMECBWN Moderate Decreased metabolism of Anagrelide caused by Riluzole mediated inhibition of CYP450 enzyme. Motor neuron disease [8B60] [29]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Anagrelide and Panobinostat. Multiple myeloma [2A83] [58]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Anagrelide and Thalidomide. Multiple myeloma [2A83] [29]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Siponimod. Multiple sclerosis [8A40] [29]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Fingolimod. Multiple sclerosis [8A40] [28]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Ozanimod. Multiple sclerosis [8A40] [59]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Anagrelide and Romidepsin. Mycosis fungoides [2B01] [28]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Anagrelide and Nilotinib. Myeloproliferative neoplasm [2A20] [28]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Anagrelide and Dasatinib. Myeloproliferative neoplasm [2A20] [28]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Anagrelide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [37]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Anagrelide and Prasugrel. Myocardial infarction [BA41-BA43] [30]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Anagrelide and Vorapaxar. Myocardial infarction [BA41-BA43] [60]
Tirofiban DMQG17S Major Increased risk of bleeding by the combination of Anagrelide and Tirofiban. Myocardial infarction [BA41-BA43] [61]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Anagrelide and Droperidol. Nausea/vomiting [MD90] [28]
Prochlorperazine DM53SRA Major Increased risk of prolong QT interval by the combination of Anagrelide and Prochlorperazine. Nausea/vomiting [MD90] [28]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Anagrelide and Promethazine. Nausea/vomiting [MD90] [28]
Palonosetron DMBHMOX Major Increased risk of prolong QT interval by the combination of Anagrelide and Palonosetron. Nausea/vomiting [MD90] [28]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Anagrelide and Granisetron. Nausea/vomiting [MD90] [28]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Anagrelide and Dolasetron. Nausea/vomiting [MD90] [28]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Anagrelide and Ondansetron. Nausea/vomiting [MD90] [28]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Anagrelide and Entrectinib. Non-small cell lung cancer [2C25] [28]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Anagrelide and Sibutramine. Obesity [5B80-5B81] [39]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Anagrelide and Dexfenfluramine. Obesity [5B80-5B81] [39]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Anagrelide and Levomethadyl Acetate. Opioid use disorder [6C43] [30]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Anagrelide and Lofexidine. Opioid use disorder [6C43] [28]
Rofecoxib DM3P5DA Moderate Decreased metabolism of Anagrelide caused by Rofecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [34]
Diclofenac DMPIHLS Moderate Increased risk of bleeding by the combination of Anagrelide and Diclofenac. Osteoarthritis [FA00-FA05] [38]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Anagrelide and Nepafenac. Osteoarthritis [FA00-FA05] [38]
Naproxen DMZ5RGV Moderate Increased risk of bleeding by the combination of Anagrelide and Naproxen. Osteoarthritis [FA00-FA05] [38]
Olaparib DM8QB1D Moderate Increased metabolism of Anagrelide caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [29]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Anagrelide and Rucaparib. Ovarian cancer [2C73] [28]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Anagrelide and MK-4827. Ovarian cancer [2C73] [30]
Dextropropoxyphene DM23HCX Major Increased risk of prolong QT interval by the combination of Anagrelide and Dextropropoxyphene. Pain [MG30-MG3Z] [29]
Etodolac DM6WJO9 Moderate Increased risk of bleeding by the combination of Anagrelide and Etodolac. Pain [MG30-MG3Z] [38]
Diflunisal DM7EN8I Moderate Increased risk of bleeding by the combination of Anagrelide and Diflunisal. Pain [MG30-MG3Z] [38]
Ibuprofen DM8VCBE Moderate Increased risk of bleeding by the combination of Anagrelide and Ibuprofen. Pain [MG30-MG3Z] [38]
Nabumetone DMAT2XH Moderate Increased risk of bleeding by the combination of Anagrelide and Nabumetone. Pain [MG30-MG3Z] [38]
Buprenorphine DMPRI8G Major Increased risk of prolong QT interval by the combination of Anagrelide and Buprenorphine. Pain [MG30-MG3Z] [28]
Piroxicam DMTK234 Moderate Increased risk of bleeding by the combination of Anagrelide and Piroxicam. Pain [MG30-MG3Z] [38]
Acetaminophen DMUIE76 Moderate Decreased metabolism of Anagrelide caused by Acetaminophen mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [29]
Thiabendazole DM7YCK3 Moderate Decreased metabolism of Anagrelide caused by Thiabendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [34]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Anagrelide and Triclabendazole. Parasitic worm infestation [1F90] [28]
Albendazole DMYZ57N Moderate Decreased metabolism of Anagrelide caused by Albendazole mediated inhibition of CYP450 enzyme. Parasitic worm infestation [1F90] [29]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Anagrelide caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [29]
Ropinirole DMA6S1D Moderate Decreased metabolism of Anagrelide caused by Ropinirole mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [62]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Anagrelide and Pimavanserin. Parkinsonism [8A00] [28]
Apomorphine DMX38HQ Major Increased risk of prolong QT interval by the combination of Anagrelide and Apomorphine. Parkinsonism [8A00] [28]
Abametapir DM2RX0I Moderate Decreased metabolism of Anagrelide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [63]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Famotidine. Peptic ulcer [DA61] [29]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Anagrelide and Macimorelin. Pituitary gland disorder [5A60-5A61] [64]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Anagrelide and Lefamulin. Pneumonia [CA40] [28]
Ketorolac DMI4EL5 Moderate Increased risk of bleeding by the combination of Anagrelide and Ketorolac. Postoperative inflammation [1A00-CA43] [38]
Bromfenac DMKB79O Moderate Increased risk of bleeding by the combination of Anagrelide and Bromfenac. Postoperative inflammation [1A00-CA43] [38]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Anagrelide and Ritodrine. Preterm labour/delivery [JB00] [32]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Anagrelide and Degarelix. Prostate cancer [2C82] [28]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Anagrelide and ABIRATERONE. Prostate cancer [2C82] [28]
Nilutamide DMFN07X Major Increased risk of prolong QT interval by the combination of Anagrelide and Nilutamide. Prostate cancer [2C82] [28]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Anagrelide and Enzalutamide. Prostate cancer [2C82] [28]
Flutamide DMK0O7U Major Increased risk of prolong QT interval by the combination of Anagrelide and Flutamide. Prostate cancer [2C82] [28]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Anagrelide and Bicalutamide. Prostate cancer [2C82] [28]
Alfuzosin DMZVMKF Major Increased risk of prolong QT interval by the combination of Anagrelide and Alfuzosin. Prostate hyperplasia [GA90] [28]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Anagrelide and Levomepromazine. Psychotic disorder [6A20-6A25] [28]
Fluphenazine DMIT8LX Major Increased risk of prolong QT interval by the combination of Anagrelide and Fluphenazine. Psychotic disorder [6A20-6A25] [28]
Triflupromazine DMKFQJP Major Increased risk of prolong QT interval by the combination of Anagrelide and Triflupromazine. Psychotic disorder [6A20-6A25] [28]
Treprostinil DMTIQF3 Moderate Increased risk of bleeding by the combination of Anagrelide and Treprostinil. Pulmonary hypertension [BB01] [65]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Anagrelide and Epoprostenol. Pulmonary hypertension [BB01] [65]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Anagrelide and Iloprost. Pulmonary hypertension [BB01] [65]
Axitinib DMGVH6N Moderate Decreased metabolism of Anagrelide caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [29]
Sorafenib DMS8IFC Major Increased risk of prolong QT interval by the combination of Anagrelide and Sorafenib. Renal cell carcinoma [2C90] [28]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Anagrelide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [66]
Meloxicam DM2AR7L Moderate Increased risk of bleeding by the combination of Anagrelide and Meloxicam. Rheumatoid arthritis [FA20] [38]
Sulindac DM2QHZU Moderate Increased risk of bleeding by the combination of Anagrelide and Sulindac. Rheumatoid arthritis [FA20] [38]
Oxaprozin DM9UB0P Moderate Increased risk of bleeding by the combination of Anagrelide and Oxaprozin. Rheumatoid arthritis [FA20] [38]
Flurbiprofen DMGN4BY Moderate Increased risk of bleeding by the combination of Anagrelide and Flurbiprofen. Rheumatoid arthritis [FA20] [38]
Fenoprofen DML5VQ0 Moderate Increased risk of bleeding by the combination of Anagrelide and Fenoprofen. Rheumatoid arthritis [FA20] [38]
Indomethacin DMSC4A7 Moderate Increased risk of bleeding by the combination of Anagrelide and Indomethacin. Rheumatoid arthritis [FA20] [38]
Tolmetin DMWUIJE Moderate Increased risk of bleeding by the combination of Anagrelide and Tolmetin. Rheumatoid arthritis [FA20] [38]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Anagrelide and Quetiapine. Schizophrenia [6A20] [28]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Anagrelide and Mesoridazine. Schizophrenia [6A20] [28]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Anagrelide and Thioridazine. Schizophrenia [6A20] [28]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Anagrelide and Aripiprazole. Schizophrenia [6A20] [29]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Anagrelide and Iloperidone. Schizophrenia [6A20] [28]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Anagrelide and Paliperidone. Schizophrenia [6A20] [28]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Anagrelide and Haloperidol. Schizophrenia [6A20] [28]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Anagrelide and Perphenazine. Schizophrenia [6A20] [28]
Chlorpromazine DMBGZI3 Major Increased risk of prolong QT interval by the combination of Anagrelide and Chlorpromazine. Schizophrenia [6A20] [28]
Clozapine DMFC71L Major Increased risk of prolong QT interval by the combination of Anagrelide and Clozapine. Schizophrenia [6A20] [28]
Trifluoperazine DMKBYWI Major Increased risk of prolong QT interval by the combination of Anagrelide and Trifluoperazine. Schizophrenia [6A20] [28]
Risperidone DMN6DXL Major Increased risk of prolong QT interval by the combination of Anagrelide and Risperidone. Schizophrenia [6A20] [28]
Olanzapine DMPFN6Y Moderate Decreased metabolism of Anagrelide caused by Olanzapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [67]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Anagrelide and Amisulpride. Schizophrenia [6A20] [28]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Anagrelide and Asenapine. Schizophrenia [6A20] [28]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Anagrelide and Pimozide. Schizophrenia [6A20] [30]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Anagrelide and Vardenafil. Sexual dysfunction [HA00-HA01] [28]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Anagrelide and LEE011. Solid tumour/cancer [2A00-2F9Z] [28]
Epirubicin DMPDW6T Major Increased risk of prolong QT interval by the combination of Anagrelide and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [28]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Anagrelide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [28]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Anagrelide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [28]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Anagrelide and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [28]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Anagrelide and Pitolisant. Somnolence [MG42] [28]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Anagrelide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [28]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Anagrelide and Ibutilide. Supraventricular tachyarrhythmia [BC81] [28]
Adenosine DMM2NSK Major Increased risk of ventricular arrhythmias by the combination of Anagrelide and Adenosine. Supraventricular tachyarrhythmia [BC81] [68]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Anagrelide and Caplacizumab. Thrombocytopenia [3B64] [29]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Anagrelide and Apixaban. Thrombosis [DB61-GB90] [30]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Anagrelide and Brilinta. Thrombosis [DB61-GB90] [30]
Argatroban DMFI46A Major Increased risk of bleeding by the combination of Anagrelide and Argatroban. Thrombosis [DB61-GB90] [69]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Anagrelide and Lenvatinib. Thyroid cancer [2D10] [28]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Anagrelide and Cabozantinib. Thyroid cancer [2D10] [28]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Anagrelide and Papaverine. Tonus and reflex abnormality [MB47] [70]
Tizanidine DMR2IQ4 Major Decreased metabolism of Anagrelide caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [71]
Tacrolimus DMZ7XNQ Major Increased risk of prolong QT interval by the combination of Anagrelide and Tacrolimus. Transplant rejection [NE84] [28]
Nalidixic acid DMRM0JV Moderate Decreased metabolism of Anagrelide caused by Nalidixic acid mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [34]
Enoxacin DMYTE6L Moderate Decreased metabolism of Anagrelide caused by Enoxacin mediated inhibition of CYP450 enzyme. Urinary tract infection [GC08] [34]
Astemizole DM2HN6Q Major Increased risk of prolong QT interval by the combination of Anagrelide and Astemizole. Vasomotor/allergic rhinitis [CA08] [28]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Anagrelide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [29]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Anagrelide and Betrixaban. Venous thromboembolism [BD72] [72]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Anagrelide and Disopyramide. Ventricular tachyarrhythmia [BC71] [28]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Anagrelide and Procainamide. Ventricular tachyarrhythmia [BC71] [28]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Anagrelide and Propafenone. Ventricular tachyarrhythmia [BC71] [28]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Anagrelide and Flecainide. Ventricular tachyarrhythmia [BC71] [28]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Anagrelide and Amiodarone. Ventricular tachyarrhythmia [BC71] [28]
⏷ Show the Full List of 284 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Anagrelide 0.5 mg capsule 0.5 mg Oral Capsule Oral
Anagrelide 1 mg capsule 1 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7114).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 FDA Approved Drug Products: Agrylin (anagrelide) oral capsules
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
7 Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8.
8 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
9 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
10 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
11 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
12 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
13 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
16 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
17 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
18 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
19 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
20 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
21 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
23 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
24 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
25 Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
26 Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
27 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28 Canadian Pharmacists Association.
29 Cerner Multum, Inc. "Australian Product Information.".
30 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
32 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
33 Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
34 Product Information. Agrylin (anagrelide). Roberts Pharmaceutical Corporation, Eatontown, NJ.
35 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
36 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
37 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
38 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
39 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
40 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
41 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
42 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
43 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
45 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
46 Product Information. Aptivus (tipranavir). Boehringer-Ingelheim, Ridgefield, CT.
47 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
48 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
49 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
50 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
51 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
52 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
53 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
54 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
55 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
56 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
57 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
58 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
60 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
61 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
62 Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
63 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
64 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
65 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
66 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
67 Albers LJ, Ozdemir V, Marder SR, et al. "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy." J Clin Psychopharmacol 25 (2005): 170-174. [PMID: 15738749]
68 Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
69 Product Information. Acova (argatroban) SmithKline Beecham, Philadelphia, PA.
70 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
71 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
72 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.